about
Measuring health-related quality of life in chronic obstructive pulmonary disease: properties of the EQ-5D-5L and PROMIS-43 short formSurvival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel.Appropriateness of ambulatory prescriptions in Taiwan: translating claims data into initiatives.Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary interventionDosing patterns and medication adherence in bipolar disorder patients treated with lurasidone: a US retrospective claims database analysis.Evaluation of content on EQ-5D as compared to disease-specific utility measures.The Association Between the Use of Zolpidem and the Risk of Alzheimer's Disease Among Older People.Residual Risk Factors to Predict Major Adverse Cardiovascular Events in Atherosclerotic Cardiovascular Disease Patients with and without Diabetes Mellitus.Lipid lowering therapy in patients with atherosclerotic cardiovascular diseases: Which matters in the real world? Statin intensity or low-density lipoprotein cholesterol level? ‒ Data from a multicenter registry cohort study in Taiwan.Patient Experience-based Value Sets: Are They Stable?Positive Outcomes of Varicose Vein Surgery: The Patient Perspective.Evaluating change using patient-reported outcome measures in knee replacement: the complementary nature of the EQ-5D index and VAS scores.Effects of clinical decision support on venous thromboembolism risk assessment, prophylaxis, and prevention at a university teaching hospital.Evaluation of changes in guidelines for medication management of stable chronic obstructive pulmonary disease.Utilization of cardiothoracic surgeons for operative penetrating thoracic trauma and its impact on clinical outcomesAge-associated impact on presentation and outcome for penetrating thoracic trauma in the adult and pediatric patient populationsThe incidence of acute venous injury as a result of proximity penetrating trauma screened with colour flow duplex ultrasoundAssociation between nonsteroidal anti-inflammatory drugs and atrial fibrillation among a middle-aged population: a nationwide population-based cohortRenoprotective Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Diabetic Patients with ProteinuriaStatin use associated with lower risk of epilepsy after intracranial haemorrhage: A population-based cohort studyQuality-adjusted Outcomes Stratified by Response in Patients With Advanced Non-Small-cell Lung Cancer Receiving First-line nab-Paclitaxel/Carboplatin or Paclitaxel/CarboplatinOn-treatment lipid profiles to predict the cardiovascular outcomes in ASCVD patients comorbid with chronic kidney disease - The multi-center T-SPARCLE registry studyA Web-Based Clinical System for Cohort Surveillance of Specific Clinical Effectiveness and Safety Outcomes: A Cohort Study of Non-Vitamin K Antagonist Oral Anticoagulants and Warfarin
P50
Q30581735-1E84F8AD-612D-4F53-844D-9DD7DBD1DD80Q33423320-B28C1A44-3B80-4A61-89CE-308956D56FD5Q34090206-86B52F0B-52BC-4EF4-BDAD-761E4201B051Q34166239-67744095-09F6-4EE5-BA8F-F7563E9D13F3Q37514635-7002427C-D301-4DC3-9732-E4FE76A6EBDEQ38021389-6797756B-8579-471C-9BDC-C9181CBB7BB8Q40051486-F0A7E471-0BFC-418D-A018-50D68E8B72DDQ41503767-02B6E5A5-052F-44FA-88CF-C0D0C857D855Q47152734-EAA755A6-DB15-418C-B96C-181456F9B3F1Q47740620-E4CC8E3C-C8B5-4745-A2D0-A46CFF2C28E7Q48061792-B6B406EB-303F-4D0A-9A9B-51EA2DBC2EFCQ48225678-52EF1AEF-9E98-4272-A5E6-2AA3972D62BAQ51759037-87135BC6-C12E-48AB-9895-50E0E34DD81EQ53125505-18A06BBB-4E2E-4003-A474-97E625470835Q87016758-96261D13-7A08-4182-9B84-4C95254532C3Q87155341-89556143-B8E0-4E87-9244-0A049A783748Q87437960-72A6F477-3989-4878-844E-65D2218E82C8Q88116030-649C3455-95BC-46B8-A549-82D80E2163BCQ88320190-13A2C399-0185-4F4E-91D0-CACAFAB314D1Q88530856-8854D44B-A0F7-4842-9F67-981EA95FBAD2Q89106744-C304EB8B-97A8-4695-9BA4-389DEA68C426Q89265644-E7D70BD0-CF22-40F0-B3D3-9372920EF430Q91601311-71AACE20-BCD1-47B0-B008-C2B766681E30
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Fang-Ju Lin
@ast
Fang-Ju Lin
@en
Fang-Ju Lin
@es
Fang-Ju Lin
@nl
type
label
Fang-Ju Lin
@ast
Fang-Ju Lin
@en
Fang-Ju Lin
@es
Fang-Ju Lin
@nl
prefLabel
Fang-Ju Lin
@ast
Fang-Ju Lin
@en
Fang-Ju Lin
@es
Fang-Ju Lin
@nl
P106
P1153
55234486700
P31
P496
0000-0002-8249-7481